MediPal : Notice Regarding Business Transfer of Consolidated Subsidiary

Published October 28, 2025 at 6:38 a.m. UTC

Source: MarketScreener

Notice Regarding Business Transfer of Consolidated Subsidiary

The Business of PharField Corporation, a Wholly Owned Subsidiary of MEDIPAL HOLDINGS CORPORATION, will be Transferred to A2 Healthcare Corporation,

a Wholly Owned Subsidiary of ITOCHU Corporation

October 28, 2025 MEDIPAL HOLDINGS CORPORATION

MEDIPAL HOLDINGS CORPORATION (headquarters: Chuo-ku, Tokyo; President and CEO: Shuichi Watanabe; "MEDIPAL") announces that it has decided to transfer the business of its wholly owned subsidiary, PharField Corporation (headquarters: Koto-ku, Tokyo; President and CEO: Tsukasa Yamaguchi; "PharField"), to A2 Healthcare Corporation (headquarters: Bunkyo-ku, Tokyo; President and CEO: Hitoshi Kamiya; "A2 Healthcare"), a wholly owned subsidiary of ITOCHU Corporation (headquarters: Minato-ku, Tokyo; President and COO: Keita Ishii; "ITOCHU").

Pharfield was established in October 2020 by taking over the PMS (Post-Marketing Surveillance) business of MEDIPAL Group's wholly owned subsidiaries, MEDICEO CORPORATION, EVERLTH Co., Ltd., and ATOL CO., LTD, through a company split.

A2 Healthcare has an Evidence Solutions Department, a group of professionals who provides a wide range of drug fostering and evolution evidence, and has an impressive track record in clinical research and trials. In addition, A2 Healthcare has previously collaborated with Falfield on PMS monitoring work. For these reasons, MEDIPAL believes that this business transfer will bring new knowledge to A2 Healthcare, enable the company to provide one-stop services to its clients, strengthen its clinical development support system, and increase added value.

The MEDIPAL Group will continue to strive to build a system that provides comprehensive support from the clinical trial stage through to market launch and distribution, thereby making further contributions to resolving various issues in the domestic pharmaceutical market, such as eliminating drug lag and loss by supporting overseas manufacturers in introducing drugs that are not approved in Japan, and ensuring a stable supply of generic drugs.

The business transfer is scheduled to take place on November 1, 2025, with the Pharfield business being transferred to A2 Healthcare. The impact of this business transfer on the MEDIPAL's consolidated financial results for the fiscal year ending March 31, 2026 is expected to be minor.

About A2 Healthcare Corporation

Location	20th Floor, Sumitomo Fudosan Korakuen Bldg., 1-4-1, Koishikawa, Bunkyo-ku, Tokyo
Representative	Hitoshi Kamiya
Established	July 2003
Scope of business	Development of pharmaceuticals, medical devices, regenerative medicine products, and vaccines Post-marketing Surveillance and clinical research services Clinical research contract business
Website	https://www.a2healthcare.com/en/

About PharField Corporation

Location	2-8-20, Saga, Koto-ku, Tokyo
Representative	Tsukasa Yamaguchi
Established	October 2020
Scope of business	Contract-based epidemiological studies clinical studies, etc.
Website	https://http://phar-field.com/ (Japanese site)

CONTACT:

MEDIPAL HOLDINGS CORPORATION

Public Relations Department Tel: +81-3-3517-5171

# # #

The English version of this document is a translation of the Japanese original and is provided for information purposes only. While reasonable efforts have been made to provide an accurate translation, no liability is assumed by MEDIPAL HOLDINGS CORPORATION for any errors, omissions, or ambiguities in the translation. In the event of any inconsistency or conflict between the English version and the Japanese original, the Japanese original shall prevail.